BPC-157 vs Sildenafil
Extensively Studied vs FDA Approved
compatible Researched · 90% No known pharmacological interaction. BPC-157's effects on angiogenesis and NO system may theoretically complement sildenafil, though clinical data on the combination is lacking.
Molecular Data
BPC-157 Sildenafil
Weight 1,419.53 Da 474.58 Da
Half-life <30 minutes ~3-5 hours
Chain 15 amino acids —
Type Pentadecapeptide Small molecule phosphodiesterase type 5 (PDE5) inhibitor
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Sildenafil
01 First and most extensively studied PDE5 inhibitor with over 25 years of clinical data
02 Rapid onset of action (30-60 minutes) allows event-based dosing
03 FDA-approved for both erectile dysfunction (Viagra) and pulmonary arterial hypertension (Revatio)
04 Flexible dosing range (25-100mg) permits individualized titration
05 Shorter duration of action may be preferred by patients who want time-limited pharmacological effect
06 Extensive generic availability makes it one of the most affordable PDE5 inhibitors
07 Well-established safety profile across diverse patient populations
08 Proven efficacy in difficult-to-treat ED including diabetic and post-prostatectomy patients
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Sildenafil
50mg as-needed (range 25-100mg) / As needed, max once per 24 hours
PAH (IV, when oral not feasible) 10mg (equivalent to 20mg oral) Three times daily as IV bolus
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Sildenafil
Headache (16% incidence, most common side effect)
Flushing / warmth (10%, due to systemic vasodilation)
Dyspepsia / indigestion (7%)
Nasal congestion / rhinitis (4%)
Visual disturbances -- blue-tinged vision, increased brightness perception, blurred vision (3%, due to PDE6 cross-reactivity in retinal photoreceptors)
Dizziness (2%)
Diarrhea (3%)
Rash (2%)
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Concurrent use of any organic nitrate medication (absolute contraindication)
Concurrent use of guanylate cyclase stimulators (e.g., riociguat)
Known hypersensitivity to sildenafil or any tablet excipient
Severe hepatic impairment (starting dose 25mg recommended in moderate impairment)
Severe renal impairment with CrCl <30 mL/min (starting dose 25mg recommended)
Recent stroke or myocardial infarction (within 6 months per original labeling)
Unstable angina or angina during sexual intercourse
Uncontrolled hypertension or symptomatic hypotension (resting BP <90/50 mmHg)
Hereditary degenerative retinal disorders including retinitis pigmentosa
History of NAION (relative contraindication -- increased recurrence risk)
Conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia)
Research Evidence
BPC-157 Sildenafil
Status Extensively Studied FDA Approved
References 8 studies 5 studies
Latest July 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.